Ruby A. Escobedo

This study shows that mice vaccinated with a single-cycle influenza virus or a neuraminidase-decorated nanoparticle are protected from lethal H5N1 influenza challenge.

This study identifies critical residues in SARS-CoV-2 Nsp1 that determine viral pathogenicity in mice by reducing replication and immune response severity.

This paper develops a multivalent live-attenuated influenza vaccine that provides broad protection against multiple H5N1 clades by incorporating HA and NA from representative clades, showing robust immune responses and protection in mice.

This study investigates the antiviral activity and mechanism of 4'-fluoroadenosine against viral and host polymerases, showing broad-spectrum inhibition and potential for drug development.

This paper shows halofuginone inhibits mammarenavirus replication by targeting prolyl-tRNA synthetase, leading to translation inhibition and reduced viral budding.

This paper develops a bioluminescent H5N1 influenza virus to track infection and test antiviral drugs in vitro and in vivo.

This paper develops a live attenuated vaccine candidate, LPhTXdNS1, against H5N1 influenza viruses and shows it is safe, immunogenic, and protective in mice.

This study identifies amino acid changes in the PB2 protein of H5N1 HPAIV that enhance replication and pathogenicity in human cells and mice.

This study compares replication and pathogenicity of cattle-origin H5N1 influenza viruses in mammals and birds, finding higher replication efficiency and pathogenicity in human-adapted isolates.